Identification of equine in vitro metabolites of seven non‐steroidal selective androgen receptor modulators for doping control purposes
- 29 October 2021
- journal article
- research article
- Published by Wiley in Drug Testing and Analysis
- Vol. 14 (2) , 349-370
Abstract
Selective androgen receptor modulators, SARMs, are a large class of compounds developed to provide therapeutic anabolic effects with minimal androgenic side effects. A wide range of these compounds are available to purchase online, and thus provide the potential for abuse in sports. Knowledge of the metabolism of these compounds is essential to aid their detection in doping control samples. In vitro models allow a quick, cost-effective response where administration studies are yet to be carried out. In this study, the equine phase I metabolism of the non-steroidal SARMs GSK2881078, LGD-2226, LGD-3303, PF-06260414, ACP-105, RAD-140 and S-23 was investigated using equine liver microsomes. Liquid chromatography coupled to a QExactive Orbitrap mass spectrometer allowed identification of metabolites with high resolution and mass accuracy. Three metabolites were identified for both GSK2881078 and LGD-2226, four for LGD-3303 and RAD-140, five for PF-06260414, twelve for ACP-105 and ten for S-23. The equine metabolism of GSK-2881078, LGD-2226, LGD-3303 and PF-06260414 is reported for the first time. Although the equine metabolism of ACP-105, RAD-140 and S-23 has previously been reported, the results obtained in this study have been compared with published data.Keywords
This publication has 36 references indexed in Scilit:
- Expanding sports drug testing assays: Mass spectrometric characterization of the selective androgen receptor modulator drug candidates RAD140 and ACP‐105Rapid Communications in Mass Spectrometry, 2013
- Characterization of In Vitro Synthesized Equine Metabolites of the Selective Androgen Receptor Modulators S24 and S4Journal of Equine Veterinary Science, 2012
- Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140ACS Medicinal Chemistry Letters, 2010
- Characterization of in vitro generated metabolites of the selective androgen receptor modulators S‐22 and S‐23 and in vivo comparison to post‐administration canine urine specimensDrug Testing and Analysis, 2010
- Synthesis, Structure−Activity Relationships, and Characterization of Novel Nonsteroidal and Selective Androgen Receptor ModulatorsJournal of Medicinal Chemistry, 2009
- Pharmacokinetics and Pharmacodynamics of LGD-3303 [9-Chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3 H-pyrrolo-[3,2-f]quinolin-7(6 H)-one], an Orally Available Nonsteroidal-Selective Androgen Receptor ModulatorThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Preclinical Characterization of a (S)-N-(4-Cyano-3-Trifluoromethyl-Phenyl)-3-(3-Fluoro, 4-Chlorophenoxy)-2-Hydroxy-2-Methyl-Propanamide: A Selective Androgen Receptor Modulator for Hormonal Male ContraceptionEndocrinology, 2008
- Mass spectrometry of selective androgen receptor modulatorsJournal of Mass Spectrometry, 2008
- Screening for 2‐quinolinone‐derived selective androgen receptor agonists in doping control analysisRapid Communications in Mass Spectrometry, 2007
- Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs)Drug Discovery Today, 2007